Potential New 2nd line Therapy for PBC

Seladelpar (CymaBay) may replace obeticholic acid as a second line therapy for PBC. About 40% of patient with PBC may not respond to Ursodeoxycholic acid (UDCA) which is the current first line therapy. Similarly, half of patient's fail to respond to obeticholic acid.


11 views0 comments

Recent Posts

See All